What insurance policy changes affect code G40.301?

There are 3 tracked policy changes affecting code G40.301, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G40.301?

Payers that have issued tracked updates for code G40.301 include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code G40.301 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G40.301. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G40.301?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

G40.301 Insurance Policy Changes

ICD-10 G40.301 is officially defined as "Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus." code G40.301 is referenced in 3 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G40.301 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective May 15, 2026High impact
Positron Emission Tomography (PET) – Head Imaging 6.01.47
Effective May 15, 2026, Excellus BCBS policy 6.01.47 sets the criteria for PET head imaging, which were removed from CMP 6.01.07. The 01/22/26 update added a medically necessary statement for amyloid brain PET (CPT 78814 or 78811) when a diagnosis of MCI or dementia due to Alzheimer disease is suspected, and a statement that perfusion PET brain (CPT 78609) is not medically necessary in the evaluation of dementia. FDG brain PET (CPT 78608) is medically necessary for mild cognitive impairment, dementia evaluation, Lewy body dementia versus Alzheimer disease, suspected encephalitis, and pre-surgical evaluation of refractory seizure when all listed criteria are met, and it is not medically necessary for Parkinson disease, normal pressure hydrocephalus, or chronic traumatic encephalopathy.
Excellus BlueCross BlueShield · Effective Aug 20, 2026Medium impact
Vagus Nerve Stimulation and Vagus Nerve Blocking Therapy 7.01.05
Implanted vagus nerve stimulation is medically appropriate as a treatment for medically refractory seizures, and it is investigational as a treatment for depression or any other non-epileptic condition. Vagus nerve stimulation implants that detect and stimulate based on increased heart rate, such as the AspireSR Model, are investigational for all indications, and vagus nerve blocking therapy is investigational as a treatment for morbid obesity. The August 20, 2026 update was an annual review with the policy intent unchanged.
Aetna · Identified Aug 18, 2026Medium impact
Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)
Aetna considers hospitalization for initiation of a ketogenic diet medically necessary for intractable seizures, including Doose syndrome and Lennox-Gastaut syndrome, when all listed selection criteria are met, and for persons with glucose transporter protein type 1 deficiency or pyruvate dehydrogenase complex deficiency. Aetna considers hospitalization for initiation of a ketogenic diet of unproven value for all other indications, including adult super-refractory status epilepticus, Alzheimer's disease, autism spectrum disorder, cancer, migraine prevention, multiple sclerosis, Parkinson's disease, schizophrenia and type 2 diabetes. Hospitalization for initiation of the Atkins diet for intractable seizures, mitochondrial diseases, or other indications is considered experimental, investigational, or unproven.

Watch G40.301

Get one email when a payer policy names G40.301, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Positron Emission Tomography (PET) – Head Imaging 6.01.47

Vagus Nerve Stimulation and Vagus Nerve Blocking Therapy 7.01.05

Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)

What insurance policy changes affect code G40.301?

Which payers have updated policy for code G40.301?

How do I get notified when code G40.301 policy changes?

Why do payers change policies for code G40.301?